Anzeige
❌
Mehr »
Mittwoch, 18.11.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Quantensicherheit! Ist diese Aktie noch völlig unterschätzt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C5SS | ISIN: BMG889121031 | Ticker: 0RP
Tradegate
17.11.26 | 20:17
0,635 Euro
+12,39 % +0,070
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TIZIANA LIFE SCIENCES LTD Chart 1 Jahr
5-Tage-Chart
TIZIANA LIFE SCIENCES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,5950,60517.11.
0,5500,60017.11.

Aktuelle News zur TIZIANA LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London958BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its...
► Artikel lesen
09.11.Tiziana Life Sciences Ltd.: Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Scler564BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its...
► Artikel lesen
09.11.Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast356BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its...
► Artikel lesen
09.11.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer1
05.11.Tiziana Life Sciences Ltd.: Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results502Trial met primary endpoint with a statistically significant reduction in microglial activation on TSPO PET (p=0.0168)Intranasal foralumab is the first non-invasive anti-CD3 therapy that has shown a...
► Artikel lesen
02.11.Tiziana falters following mid-stage results for multiple sclerosis asset4
02.11.Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose struggles2
TIZIANA LIFE SCIENCES Aktie jetzt für 0€ handeln
02.11.Tiziana Life Sciences Ltd.: Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis355Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as...
► Artikel lesen
02.11.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer2
21.10.Tiziana Life Sciences Ltd.: Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto520BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its...
► Artikel lesen
16.10.Tiziana Life Sciences Ltd.: Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease796BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its...
► Artikel lesen
16.10.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer3
30.09.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)661BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its...
► Artikel lesen
28.09.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab471BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its...
► Artikel lesen
28.09.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer4
21.09.Tiziana Life Sciences Ltd.: Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab706BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its...
► Artikel lesen
17.09.Why Is Tiziana Life Sciences Stock Gaining Thursday?9
17.09.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center504BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its...
► Artikel lesen
17.09.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer3
10.09.Tiziana Castauro neue Co-Moderatorin bei TOP³, Marc Arnold moderiert zusätzlich «Eimol mit Profis»5
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1